BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress.
Authors: Érica M.Granjeiro, Felipe V.Gomes, Francisco S.Guimarães, Fernando M.A.Corrêa, Leonardo B.M. Resstel
Pharmacology Biochemistry and Behavior, October 2011
—
Systemic administration of cannabidiol (CBD), a non-psychotomimetic compound from Cannabis sativa, attenuates the cardiovascular and behavioral responses to restraint stress. Although the brain structures related to CBD effects are not entirely known, they could involve brains…
Review on clinical studies with cannabis and cannabinoids 2005-2009
Based on the clinical results, cannabinoids present an interesting therapeutic potential mainly as analgesics in chronic neuropathic pain, appetite stimulants in debilitating diseases (cancer and AIDS), as well as in the treatment of multiple sclerosis.
Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.
Authors: Rupal Pandey, Venkatesh L. Hegde, Mitzi Nagarkatti, Prakash S. Nagarkatti
Journal of Pharmacology and Experimental Therapeutics, September 2011
—
Allogeneic hematopoietic cell transplantation (HCT) is widely used to treat patients with life-threatening malignant and nonmalignant hematological diseases. However, allogeneic HCT often is accompanied by severe and lethal complications from graft-versus-host disease (GVHD)…
Beyond-THC Chemovar Evaluation Survey
The Society of Cannabis Clinicians developed a survey in 2011 that asked about patients’ responses to CBD-rich cannabis.
The dual neuroprotective-neurotoxic profile of cannabinoid drugs.
Authors: Yosef Sarne, Fadi Asaf, Miriam Fishbein, Mikhal Gafni, Ora Keren
British Journal of Pharmacology, August 2011
—
Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms. On the other hand, neurotoxic effects of cannabinoids in vitro and i…
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Authors: Ethan B. Russo
British Journal of Pharmacology, August 2011
—
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated…
Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.
Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011
—
Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.
Authors: Sean D. McAllister, Ryuichi Murase, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, et al
Breast Cancer Research and Treatment, August 2011
—
Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxi…
Treatment of Crohn’s disease with cannabis: an observational study.
Authors: T. Naftali, L. Bar Lev, D. Yablekovitz, E. Half, F.M. Konikoff
Israel Medical Association Journal, August 2011
—
BACKGROUND: The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn’s disease (CD) was ever published. OBJECTIVES: To describe the effects of cannabis use in pat…
SCC Hears McAllister On Cannabis Cancer Research
Researchers have discovered that CBD (Cannabidiol) is a very potent inhibitor of breast cancer metastasis. Doctors who monitor cannabis use by patients were bursting with questions during a talk by Sean McAllister, PhD, who has been studying the anti-cancer effects of cannabinoids in the laboratory.
Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.
Authors: D. Vara, M. Salazar, N. Olea-Herrero, M. Guzmán, G. Velasco, I. Díaz-Laviada
Cell Death and Differentiation, July 2011
—
Hepatocellular carcinoma (HCC) is the third cause of cancer-related death worldwide. When these tumors are in advanced stages, few therapeutic options are available. Therefore, it is essential to search for new treatments to fight this disease. In this study, we investigated t…
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.
Authors: Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, Anil Prasad
Molecular Cancer Therapeutics, July 2011
—
Cannabidiol (CBD), a major nonpsychoactive constituent of cannabis, is considered an antineoplastic agent on the basis of its in vitro and in vivo activity against tumor cells. However, the exact molecular mechanism through which CBD mediates this activity is yet to be elucida…